419 related articles for article (PubMed ID: 24009294)
1. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
2. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Saklayen MG; Gyebi LK; Tasosa J; Yap J
J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
6. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
7. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
9. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
Kim HY; Bae EH; Ma SK; Kim SW
Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
11. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
[TBL] [Abstract][Full Text] [Related]
12. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
14. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
[TBL] [Abstract][Full Text] [Related]
15. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
[TBL] [Abstract][Full Text] [Related]
16. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
17. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
Sun LJ; Sun YN; Shan JP; Jiang GR
J Diabetes Investig; 2017 Jul; 8(4):609-618. PubMed ID: 28107779
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
Hou J; Xiong W; Cao L; Wen X; Li A
Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
